*First day when ANC dropped below 0.1 × 10⁹/L.

First day when platelets dropped below 20 × 10⁹/L.

First day when ANC rose above 0.5 × 10⁹/L.

First day platelet count rose above 20 × 10⁹/L; transfusion independent.

GVHD initiated when patient was on CSA therapy.

¶GVHD initiated when patient was off CSA therapy.

#Donor was a single locus A and C mismatched sibling, with a positive one way host anti-donor mixed lymphocyte culture.

Alive and well, including patients with chronic GVHD, which was not extensive in any of the patients.

Patient with hematologic relapse 8 months following allogeneic nonmyeloablative stem cell transplantation currently under remission induction with a combination of chemotherapy for tumor debulking and allogeneic cell therapy (alloCT), in parallel with development of grade 2 GVHD.

Patient with overt hematologic relapse at 4 months following allogeneic nonmyeloblative stem cell transplantation successfully treated by a combination of chemotherapy for tumor debulking and allogeneic cell therapy T, in parallel with development of grade 2 GVHD, with no evidence of diseases, with 100% donor-type (female) cells by cytogenetic analysis and no male cells by PCR.

Male patient with tumor cells completely resistant to all chemotherapy at the time of admission, with residual disease following allogeneic non-myeloablative stem cell transplantation with marrow infiltration with lymphoma cells, successfully treated with allogeneic cell therapy in parallel with development of grade 2 GVHD, currently with no evidence of diseases, with 100% donor-type (female) cells by cytogenetic analysis and no male cells by PCR.

Patient with no hematologic evidence of disease treated with allogeneic cell therapy for cytogenetic relapse with positive bcr-abl RT-PCR.